Pliant Therapeutics (PLRX) Stock Forecast & Price Target

$13.37

+0.06 (+0.45%)

(As of 07/26/2024 ET)

Pliant Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 9 Analyst Ratings

Based on 9 Wall Street analysts who have issued ratings for Pliant Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 9 analysts, 9 have given a buy rating for PLRX.

Consensus Price Target

$45.38
239.38% Upside

High Forecast	$63.00
Average Forecast	$45.38
Low Forecast	$36.00

According to the 9 analysts' twelve-month price targets for Pliant Therapeutics, the average price target is $45.38. The highest price target for PLRX is $63.00, while the lowest price target for PLRX is $36.00. The average price target represents a forecasted upside of 239.38% from the current price of $13.37.

Type	Current Forecast 7/27/23 to 7/26/24	1 Month Ago 6/27/23 to 6/26/24	3 Months Ago 4/28/23 to 4/27/24	1 Year Ago 7/27/22 to 7/27/23
Consensus Rating	Buy	Buy	Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)	11 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$45.38	$45.38	$49.00	$48.55
Forecasted Upside	239.38% Upside	208.80% Upside	180.38% Upside	84.38% Upside

Get Pliant Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.

Ad WealthPress

This TSLA short trade is on a nine win hot streak

Most Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.

But I can promise that you’ll see all the details for yourself here.

PLRX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PLRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Pliant Therapeutics Stock vs. The Competition

Type	Pliant Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.72	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	240.65% Upside	2,847.92% Upside	8.98% Upside
News Sentiment Rating	Very Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/16/2024	Needham & Company LLC 3 of 5 stars		Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00	+179.00%
7/16/2024	HC Wainwright 3 of 5 stars		Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00	+172.11%
5/7/2024	Citigroup 3 of 5 stars		Lower Target	Buy ➝ Buy	$45.00 ➝ $44.00	+223.53%
5/7/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$54.00 ➝ $45.00	+222.58%
5/7/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$47.00 ➝ $48.00	+248.08%
12/8/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$41.00	+178.91%
Get the Latest News and Ratings for PLRX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
10/16/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
8/22/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Stavropoulos Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$63.00	+271.02%
8/10/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$47.00 ➝ $48.00	+150.00%
5/18/2023	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$48.00	+122.94%
4/12/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$44.00	+73.23%
1/24/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$33.00 ➝ $45.00	+48.61%
12/13/2022	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$33.00	+73.23%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 10:14 PM ET.

PLRX Forecast - Frequently Asked Questions

What is Pliant Therapeutics' forecast for 2024?: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Pliant Therapeutics is $45.38, with a high forecast of $63.00 and a low forecast of $36.00.
Should I buy or sell Pliant Therapeutics stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PLRX shares.
Does Pliant Therapeutics's stock price have much upside?: According to analysts, Pliant Therapeutics's stock has a predicted upside of 204.86% based on their 12-month stock forecasts.
What analysts cover Pliant Therapeutics?: Pliant Therapeutics has been rated by research analysts at Citigroup, HC Wainwright, Needham & Company LLC, Oppenheimer, and Royal Bank of Canada in the past 90 days.
Do Wall Street analysts like Pliant Therapeutics more than its competitors?: Analysts like Pliant Therapeutics more than other "medical" companies. The consensus rating for Pliant Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PLRX compares to other companies.